The human gut microbiome, malnutrition and vaccine responses
人类肠道微生物组、营养不良和疫苗反应
基本信息
- 批准号:8469030
- 负责人:
- 金额:$ 6.2万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2011
- 资助国家:美国
- 起止时间:2011-07-04 至 2014-07-03
- 项目状态:已结题
- 来源:
- 关键词:AddressAdjuvantAgeAgricultureAnimalsAntigensArchaeaAreaBacteriaBiological AssayBiological MarkersBirthCellsCessation of lifeChildChildhoodCholera ToxinCommunitiesDNADefectDevelopmentDietDiet MonitoringEndotoxinsEnteralEnzyme-Linked Immunosorbent AssayExcretory functionExhibitsFailureFamilyFemaleFetal MalnutritionFoodFreezingGene ExpressionGenesGerm-FreeGleanGnotobioticHarvestHistologyHumanImmuneImmune systemImmunoglobulin AImmunoglobulin GInfantInfectionInterventionIntestinesKwashiorkorLactuloseLeadLifeLinkLongitudinal StudiesMacronutrients NutritionMalawiMalnutritionMannitolMessenger RNAMetabolicMetagenomicsMethodsMicronutrientsModelingMonitorMonozygotic TwinningMonozygotic twinsMorbidity - disease rateMorphologyMothersMucosal Immune ResponsesMucosal ImmunityMusNational Research Service AwardsNeurodevelopmental DeficitNutrientNutritionalNutritional SupportNutritional statusOralOvalbuminPartner in relationshipPathogenesisPatternPhysiologicalPneumoniaPopulationPredispositionPregnancyProtocols documentationRecurrenceRelative (related person)Ribosomal RNARoleSamplingSeriesSerumShapesShotgunsSiblingsStructureSurveysTestingTherapeuticTherapeutic UsesTimeTranslationsTransplantationTwin Multiple BirthVaccinatedVaccinationVaccine DesignVaccinesWeaningWithdrawalabsorptionageddesigndisorder riskexpectationfeedingfunctional genomicsglobal healthgut microbiotaimmune functioninsightkillingsmembermicrobialmicrobial communitymicrobiomemicronutrient deficiencymortalitymouse modelmucosal vaccinationoffspringpostnatalpregnantpuppyrosequencingrRNA Genesresearch studyresponsetranscriptome sequencingtransmission process
项目摘要
DESCRIPTION (provided by applicant): Malnutrition kills millions of children worldwide every year. Much of their morbidity and mortality is a result of infections, including those caused by enteropathogens. Efforts to stop these infections have been limited in some populations by unexplained vaccine failures. I hypothesize that there is an interrelationship between malnutrition, the gut microbiome, and the immune system that is causally linked with vaccine responsiveness and that these interrelationships can be informatively probed using 'humanized' gnotobiotic mice. Our lab is conducting longitudinal studies of the gut microbiomes of twins aged 1-36 months living in Malawi who are healthy, or who are concordant or discordant for severe forms of malnutrition (e.g., kwashiorkor). We are addressing the following questions: Are there identifiable configurations of the gut microbiome associated with severe forms of malnutrition? How is the microbiota/microbiome reconfigured with a Ready to Use Therapeutic Food (RUTF) intervention and does it persist after cessation of RUTF? If the configured state does not persist after withdrawal of RUTF, does this mean that in the absence of longer-term nutritional support, lingering abnormalities in the metabolic activities contribute to persistent physiological abnormalities in the human host? We have recently shown that it is possible to efficiently transplant the microbial community present in frozen human fecal samples into germ-free (GF) mice and to transmit the engrafted microbiota from mothers to their offspring. With this capability, I propose two aims for this NRSA application. Aim 1. Use gnotobiotic mice, colonized at 6 weeks of age with de-identified fecal microbiota already collected from several sets of monozygotic twins discordant for kwashiorkor (1 healthy/ 1 malnourished) as well as their mothers' microbiota. Recipients will be fed a macro- and micronutrient deficient Malawi diet, or a control nutritionally 'sufficient' diet. I will follow their responses to mucosal vaccination with cholera toxin and ovalbumin (a model mucosal adjuvant/antigen) using antigen-specific ELISA. I will define their gut mucosal barrier function by serum LPS assays, lactulose/mannitol absorption assays, histo- and immunohistochemical assays of gut morphology and immune cell populations (exploring whether they have features of tropical enteropathy), plus functional genomic studies of gut gene expression. I will perform time series metagenomic studies on their fecal microbiomes (sequencing bacterial 16S rRNA genes, total community DNA, and expressed mRNAs). Aim 2. Assess the role of maternal nutritional and microbiota 'status' on the vaccine responses of their offspring by colonizing pregnant female GF mice with fecal samples from twins discordant for kwashiorkor and their mothers. Mothers will be maintained on either a Malawi or nutrient- sufficient control diet prior to, during and after pregnancy; their offspring will be weaned onto nutrient- deficient or -sufficient diets and subjected to the same vaccination protocols and analyses as described in Aim 1. These experiments should help identify biomarkers of malnutrition and vaccine responsiveness.
描述(由申请人提供):营养不良每年导致全世界数百万儿童死亡。其大部分发病率和死亡率是感染造成的,包括肠道病原体引起的感染。由于不明原因的疫苗失败,阻止这些感染的努力在某些人群中受到限制。我假设营养不良、肠道微生物群和免疫系统之间存在相互关系,与疫苗反应性存在因果关系,并且可以使用“人源化”无菌小鼠对这些相互关系进行翔实的探索。我们的实验室正在对生活在马拉维的 1-36 个月大双胞胎的肠道微生物群进行纵向研究,这些双胞胎健康,或者严重营养不良(例如恶性营养不良)一致或不一致。我们正在解决以下问题:肠道微生物组的可识别配置是否与严重营养不良相关?即用型治疗性食品 (RUTF) 干预措施如何重新配置微生物群/微生物组,以及在 RUTF 停止后这种情况是否持续存在?如果停用RUTF后配置状态没有持续存在,这是否意味着在缺乏长期营养支持的情况下,代谢活动的持续异常会导致人类宿主持续的生理异常?我们最近表明,可以有效地将冷冻人类粪便样本中存在的微生物群落移植到无菌(GF)小鼠中,并将移植的微生物群从母亲传给后代。有了这个功能,我为这个 NRSA 应用提出了两个目标。目标 1. 使用 6 周龄定植的无菌小鼠,其粪便微生物群已从几组与恶性营养不良(1 名健康/1 名营养不良)不一致的同卵双胞胎及其母亲的微生物群中收集。接受者将接受缺乏大量营养素和微量营养素的马拉维饮食,或营养“充足”的对照饮食。我将使用抗原特异性 ELISA 跟踪他们对霍乱毒素和卵清蛋白(一种粘膜佐剂/抗原模型)粘膜疫苗接种的反应。我将通过血清 LPS 测定、乳果糖/甘露醇吸收测定、肠道形态和免疫细胞群的组织化学和免疫组织化学测定(探索它们是否具有热带肠病的特征)以及肠道基因表达的功能基因组研究来定义它们的肠道粘膜屏障功能。我将对它们的粪便微生物组进行时间序列宏基因组研究(对细菌 16S rRNA 基因、总群落 DNA 和表达的 mRNA 进行测序)。目标 2. 通过将恶性营养不良双胞胎及其母亲的粪便样本定植怀孕雌性 GF 小鼠,评估母体营养和微生物群“状态”对其后代疫苗反应的作用。母亲在怀孕前、怀孕期间和怀孕后将保持马拉维饮食或营养充足的控制饮食;他们的后代将断奶,采用营养不足或营养充足的饮食,并接受与目标 1 中所述相同的疫苗接种方案和分析。这些实验应有助于识别营养不良和疫苗反应的生物标志物。
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Anti-interleukin 4 and 13 for asthma treatment in the era of endotypes.
- DOI:10.1097/aci.0000000000000108
- 发表时间:2014-12
- 期刊:
- 影响因子:2.8
- 作者:Kau AL;Korenblat PE
- 通讯作者:Korenblat PE
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Andrew Leon Kau其他文献
Andrew Leon Kau的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Andrew Leon Kau', 18)}}的其他基金
Breathprinting as a window into gut microbiome chemoecology
呼吸印迹是了解肠道微生物组化学生态学的窗口
- 批准号:
10512356 - 财政年份:2022
- 资助金额:
$ 6.2万 - 项目类别:
Harnessing Antibody Responses to Prevent and Treat Urinary Tract Infections
利用抗体反应预防和治疗尿路感染
- 批准号:
10523527 - 财政年份:2021
- 资助金额:
$ 6.2万 - 项目类别:
Harnessing Antibody Responses to Prevent and Treat Urinary Tract Infections
利用抗体反应预防和治疗尿路感染
- 批准号:
10344461 - 财政年份:2021
- 资助金额:
$ 6.2万 - 项目类别:
Microbial Origin of Breath Volatile Metabolites
呼吸挥发性代谢物的微生物来源
- 批准号:
10171781 - 财政年份:2020
- 资助金额:
$ 6.2万 - 项目类别:
Microbial Origin of Breath Volatile Metabolites
呼吸挥发性代谢物的微生物来源
- 批准号:
10043038 - 财政年份:2020
- 资助金额:
$ 6.2万 - 项目类别:
THE MICROBIOTA AND MUCOSAL IMMUNE RESPONSES IN THE DEVELOPMENT OF ASTHMA
哮喘发生过程中的微生物群和粘膜免疫反应
- 批准号:
9211283 - 财政年份:2015
- 资助金额:
$ 6.2万 - 项目类别:
The human gut microbiome, malnutrition and vaccine responses
人类肠道微生物组、营养不良和疫苗反应
- 批准号:
8309675 - 财政年份:2011
- 资助金额:
$ 6.2万 - 项目类别:
The human gut microbiome, malnutrition and vaccine responses
人类肠道微生物组、营养不良和疫苗反应
- 批准号:
8127100 - 财政年份:2011
- 资助金额:
$ 6.2万 - 项目类别:
相似海外基金
Restoring age-dependent vaccine unresponsiveness by a novel ASP-1 adjuvant combination
通过新型 ASP-1 佐剂组合恢复年龄依赖性疫苗无反应
- 批准号:
10458553 - 财政年份:2021
- 资助金额:
$ 6.2万 - 项目类别:
Restoring age-dependent vaccine unresponsiveness by a novel ASP-1 adjuvant combination
通过新型 ASP-1 佐剂组合恢复年龄依赖性疫苗无反应
- 批准号:
10220588 - 财政年份:2021
- 资助金额:
$ 6.2万 - 项目类别:
Restoring age-dependent vaccine unresponsiveness by a novel ASP-1 adjuvant combination
通过新型 ASP-1 佐剂组合恢复年龄依赖性疫苗无反应
- 批准号:
10620718 - 财政年份:2021
- 资助金额:
$ 6.2万 - 项目类别:
CoVPN 3005 - Efficacy, Immunogenicity, and Safety of SARS-CoV-2 Recombinant Protein Vaccine with Adjuvant in Adults 18 Years of Age and Older
CoVPN 3005 - SARS-CoV-2 重组蛋白疫苗与佐剂对 18 岁及以上成人的功效、免疫原性和安全性
- 批准号:
10415762 - 财政年份:2021
- 资助金额:
$ 6.2万 - 项目类别:
Dissecting the mechanism of age-specific adjuvant synergy in vitro and in vivo
剖析年龄特异性佐剂体外和体内协同作用的机制
- 批准号:
9108575 - 财政年份:2016
- 资助金额:
$ 6.2万 - 项目类别:
CoVPN 3005: Efficacy, Immunogenicity, and Safety of Two SARS-CoV-2 Recombinant Protein Vaccines with Adjuvant in Adults 18 Years of Age and Older - LC 3
CoVPN 3005:两种 SARS-CoV-2 重组蛋白疫苗与佐剂对 18 岁及以上成人的功效、免疫原性和安全性 - LC 3
- 批准号:
10570739 - 财政年份:2006
- 资助金额:
$ 6.2万 - 项目类别:
CoVPN 3005 - Efficacy, Immunogenicity, and Safety of SARS-CoV-2 Recombinant Protein Vaccine with Adjuvant in Adults 18 Years of Age and Older
CoVPN 3005 - SARS-CoV-2 重组蛋白疫苗与佐剂对 18 岁及以上成人的功效、免疫原性和安全性
- 批准号:
10686595 - 财政年份:2006
- 资助金额:
$ 6.2万 - 项目类别:
CoVPN 3005 - Efficacy, Immunogenicity, and Safety of Two SARS-CoV-2 Recombinant Protein Vaccines with Adjuvant in Adults 18 Years of Age and Older
CoVPN 3005 - 两种 SARS-CoV-2 重组蛋白疫苗与佐剂对 18 岁及以上成年人的功效、免疫原性和安全性
- 批准号:
10581414 - 财政年份:2006
- 资助金额:
$ 6.2万 - 项目类别:
CoVPN 3005 - Efficacy, Immunogenicity, and Safety of SARS-CoV-2 Recombinant Protein Vaccine with Adjuvant in Adults 18 Years of Age and Older
CoVPN 3005 - SARS-CoV-2 重组蛋白疫苗与佐剂对 18 岁及以上成人的功效、免疫原性和安全性
- 批准号:
10579557 - 财政年份:2006
- 资助金额:
$ 6.2万 - 项目类别:














{{item.name}}会员




